Results of long-term treatment with controlled-release levodopa/carbidopa (Sinemet CR)

J. M. Cedarbaum, M. Silvestri, M. Clark, L. Toy, A. Harts, A. Green-Parsons, F. H. McDowell

Research output: Contribution to journalArticlepeer-review

6 Scopus citations

Abstract

35 Parkinson's disease patients with motor response fluctuations (RF) participated in controlled clinical trials comparing Sinemet CR to Standard Sinemet (STD) at our institutions. 13 of 25 eligible patients continued to two years (the longest possible follow-up from the second study), and 5 of 11 have continued taking CR up to 4 years. At the end of both two and four years, patients were taking significantly fewer medication doses, with a significantly longer interdose interval, and up to two years, experienced fewer "off" periods than when on Standard Sinemet (STD) alone. Most patients required STD at at least one dose each day to hasten to onset of antiparkinson effect. Sinemet CR is a useful adjunct in the long-term management of motor response fluctuations in Parkinson's disease.

Original languageEnglish
Pages (from-to)205-213
Number of pages9
JournalJournal of Neural Transmission - Parkinson's Disease and Dementia Section
Volume2
Issue number3
DOIs
StatePublished - Sep 1990
Externally publishedYes

Keywords

  • Parkinson disease
  • levodopa
  • sustained-or-controlled release

Fingerprint

Dive into the research topics of 'Results of long-term treatment with controlled-release levodopa/carbidopa (Sinemet CR)'. Together they form a unique fingerprint.

Cite this